Rohit Gosain/LinkedIn
Oct 27, 2025, 08:00
Rohit Gosain: Revumenib is Now FDA Approved for R/R AML with NPM1 Mutation
Rohit Gosain, Medical Director of Roswell Park Comprehensive Cancer Center, posted on LinkedIn:
“Revumenib is now FDA approved for R/R AML with NPM1 mutation (approved for KMT2A translocation previously).
– ORR 46.9%
– Response seen in all subgroups (comutations, previous HSCT, or high number of prior lines of Rx).”
Stay informed with Hemostasis Today.
-
Mar 11, 2026, 18:27Cesar Garrido and Lackram Bodoe Are Advancing WFH Partnerships in Trinidad and Tobago
-
Mar 11, 2026, 18:14Aloke Finn: Silent Plaque Rupture and Healing in Coronary Artery Disease
-
Mar 11, 2026, 17:23Mattia Galli: A Privilege to Collaborate on Such a Complex Topic as Cardio-Rheumatology
-
Mar 11, 2026, 17:12Shubham Misra: Proteomic Biomarkers for Acute Stroke Subtype Classification
-
Mar 11, 2026, 16:55Melanie Daniel: Modeling High-Purity von Willebrand Factor for Individualized Dosing in Surgery
-
Mar 11, 2026, 15:46Bleeding and Thrombosis Outcomes in Older Patients With Myelodysplastic Syndromes – JTH
-
Mar 11, 2026, 15:37Sonia Muliyil: The Greatest Benefit is The Wellbeing and Sustenance of Half The World’s Population
-
Mar 11, 2026, 15:34Kymentie Ferdinande: Rivaroxaban in Cirrhosis and the Path Toward Individualized Anticoagulation
-
Mar 11, 2026, 15:34Sheharyar Raza: When More Testing Isn’t Always Better in Healthy Donor Screening